Bispecific antibodies against plasma kallikrein and factor XII

US12240918B2 · kind B2 · utility

Assignee

• Takeda Pharmaceutical Company Limited · JP

Inventors

• Stephen R. Comeau · Avon, US
• Andrew Nixon · Hanover, US
• Niksa Kastrapeli · Wellesley, US
• Jon A. Kenniston · Hingham, US
• Gregory P. Conley · Arlington, US
• Shauna Mason · Arlington, US
• Allison P. Lindberg · Arlington, US
• Kristopher Kopacz · Cumberland, US
• Burt Adelman · Concord, US

Key dates

• Filing date: Jun 13, 2022
• Grant date: Mar 4, 2025
• Expiry date: Oct 18, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.